The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with ...

What Happened? Shares of healthcare products company West Pharmaceutical Services (NYSE:WST) jumped 22.9% in the afternoon ...

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood plasma cells, the British drugmaker said on Thursday.

Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing ...

FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.

Pharmaceutical tariffs are coming, part of President Trump’s stated goal of bringing drug manufacturing back to the U.S.

US Health and Human Services (HHS) Secretary Robert F Kennedy Jr has formally signed off on a recommendation to remove ...

A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a broad market rally.

A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a ...

(Alliance News) - GSK PLC on Wednesday said the US Food & Drug Administration has extended the review period for Blenrep combinations in relapsed/refractory multiple myeloma after an advisory ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...